These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 31563938)
1. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018. Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938 [TBL] [Abstract][Full Text] [Related]
2. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882 [TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia. Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172 [TBL] [Abstract][Full Text] [Related]
4. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia. Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459 [TBL] [Abstract][Full Text] [Related]
5. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. Nasrullah M; Sergeenko D; Gvinjilia L; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Alkhazashvili M; Shadaker S; Ward JW; Morgan J; Averhoff F MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(29):773-776. PubMed ID: 28749925 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. Stvilia K; Vephkvadze N; Gamkrelidze A; Khonelidze I; Getia V; Tsereteli M; Gvinjilia L; Kuchuloria T Public Health; 2021 Jun; 195():42-50. PubMed ID: 34051674 [TBL] [Abstract][Full Text] [Related]
7. Lessons Learned From Global Hepatitis C Elimination Programs. Handanagic S; Shadaker S; Drobeniuc J; Tsereteli M; Alkhazashvili M; Adesigbin C; Adamu I; Adabe R; Agwuocha C; Adisa O; Azania A; Boeke CE; Ngwije A; Serumondo J; Armstrong PA J Infect Dis; 2024 May; 229(Supplement_3):S334-S341. PubMed ID: 37739781 [TBL] [Abstract][Full Text] [Related]
8. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia. Butsashvili M; Gvinjilia L; Kamkamidze G; Metreveli D; Dvali S; Rukhadze T; Gamkrelidze A; Nasrullah M; Shadaker S; Morgan J; Averhoff F BMC Res Notes; 2020 Jul; 13(1):332. PubMed ID: 32653020 [TBL] [Abstract][Full Text] [Related]
9. Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs - Georgia, 2018. Stvilia K; Spradling PR; Asatiani A; Gogia M; Kutateladze K; Butsashvili M; Zarkua J; Tsertsvadze T; Sharvadze L; Japaridze M; Kuchuloria T; Gvinjilia L; Tskhomelidze I; Gamkrelidze A; Khonelidze I; Sergeenko D; Shadaker S; Averhoff F; Nasrullah M MMWR Morb Mortal Wkly Rep; 2019 Jul; 68(29):637-641. PubMed ID: 31344021 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 - April 2015. Harris AM; Chokoshvili O; Biddle J; Turashvili K; Japaridze M; Burjanadze I; Tsertsvadze T; Sharvadze L; Karchava M; Talakvadze A; Chakhnashvili K; Demurishvili T; Sabelashvili P; Foster M; Hagan L; Butsashvili M; Morgan J; Averhoff F BMC Public Health; 2019 May; 19(Suppl 3):466. PubMed ID: 32326938 [TBL] [Abstract][Full Text] [Related]
11. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system. Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020. Baliashvili D; Blumberg HM; Gandhi NR; Averhoff F; Benkeser D; Shadaker S; Gvinjilia L; Turdziladze A; Tukvadze N; Chincharauli M; Butsashvili M; Sharvadze L; Tsertsvadze T; Zarkua J; Kempker RR PLoS Med; 2023 May; 20(5):e1004121. PubMed ID: 37141386 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets. Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549 [TBL] [Abstract][Full Text] [Related]
14. Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era. Dupont SC; Fluker SA; Quairoli KM; Body C; Okosun I; Lom J; Miller LS Public Health Rep; 2020 Jan; 135(1):107-113. PubMed ID: 31756116 [TBL] [Abstract][Full Text] [Related]
15. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900 [TBL] [Abstract][Full Text] [Related]
16. DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C DO NOT AFFECT THE RISK OF DEVELOPMENT OR THE OUTCOME OF HEPATOCELLULAR CARCINOMA. Gogichaishvili L; Lobjanidze G; Tsertsvadze T; Chkhartishvili N; Jangavadze M Georgian Med News; 2020 Sep; (306):76-81. PubMed ID: 33130651 [TBL] [Abstract][Full Text] [Related]
17. CONFIDENCE IN THE GEORGIA NATIONAL HCV ELIMINATION PROGRAM AMONG WOMEN OF REPRODUCTIVE AGE. Gamezardashvili A; Butsashvili M; Kajaia M; Gulbiani L; Abashidze G; Kapanadze M; McNutt LA; Kamkamidze G Georgian Med News; 2019 Oct; (295):105-109. PubMed ID: 31804209 [TBL] [Abstract][Full Text] [Related]
18. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949 [TBL] [Abstract][Full Text] [Related]
19. Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020. Gvinjilia L; Baliashvili D; Shadaker S; Averhoff F; Kandelaki L; Kereselidze M; Tsertsvadze T; Chkhartishvili N; Butsashvili M; Metreveli D; Gamkrelidze A; Armstrong PA Clin Infect Dis; 2023 Aug; 77(3):405-413. PubMed ID: 37099136 [TBL] [Abstract][Full Text] [Related]
20. National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. Gvinjilia L; Nasrullah M; Sergeenko D; Tsertsvadze T; Kamkamidze G; Butsashvili M; Gamkrelidze A; Imnadze P; Kvaratskhelia V; Chkhartishvili N; Sharvadze L; Drobeniuc J; Hagan L; Ward JW; Morgan J; Averhoff F MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1132-1135. PubMed ID: 27764081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]